Regulus Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Regulus Therapeutics

09/11/2022 03:04

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 10. 
    * 
    * ​Refinitiv's mean analyst estimate for Regulus
Therapeutics Inc
is for a loss of 49 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $14.5​, above​ its last closing price
of $1.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.49       -0.48      -0.50     Missed  -3.1
 Mar. 31 2022  -0.56       -0.53      -0.50     Beat    6.2
 Dec. 31 2021  -0.62       -0.67      -0.70     Missed  -5​
 Sep. 30 2021  -0.76       -0.77      -1.00     Missed  -29
 ​​Jun.        -0.80       -0.80      -0.80     Met     0
 30 2021                                                
 Mar. 31 2021  -0.90       -0.90      -0.80     Beat    11.1​
 Dec. 31 2020  -1.00       -1.40      -0.30     Beat    78.6
 Sep. 30 2020  -2.17       -2.07      -0.40     Beat    80.7
 This summary was machine generated November 9 at 03:04 GMT.  All
figures in US dollars  unless otherwise stated